Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker BBT
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Nina A. Charnley Director | BBT Beacon Financial Corporation | Buy | 350 | $30.57 | $10.7K Buy | Form 4 ↗ |
| Oct 29, 2026 | William H. Hughes III Director | BBT Beacon Financial Corporation | Buy | 200 | $30.73 | $6,146 Buy | Form 4 ↗ |
| Oct 28, 2026 | Mary Anne Callahan Director | BBT Beacon Financial Corporation | Buy | 3,200 | $30.21 | $96.7K Buy | Form 4 ↗ |
| Oct 28, 2026 | Eric S. Rosengren Director | BBT Beacon Financial Corporation | Buy | 700 | $30.24 | $21.2K Buy | Form 4 ↗ |
| Oct 27, 2026 | Margaret Boles Fitzgerald Director | BBT Beacon Financial Corporation | Buy | 329 | $30.77 | $10.1K Buy | Form 4 ↗ |
| Oct 26, 2026 | Karyn Polito Director | BBT Beacon Financial Corporation | Buy | 1,000 | $30.68 | $30.7K Buy | Form 4 ↗ |
| Oct 26, 2026 | John Buckley Eagan General Counsel | BBT Beacon Financial Corporation | Sale | 641 | $30.61 | $19.6K Sale | Form 4 ↗ |
| Oct 26, 2026 | Thomas J. Hollister Director | BBT Beacon Financial Corporation | Buy | 3,450 | $30.43 | $105.0K Buy | Form 4 ↗ |
| Feb 26, 2026 | Michael W. McCurdy Chief Banking Officer | BBT Beacon Financial Corporation | Sale | 17,333 | $31.04 | $538.0K Sale | Form 4 ↗ |
| Nov 4, 2025 | Mary Anne Callahan Director | BBT Beacon Financial Corporation | Buy | 4,000 | $24.67 | $98.7K Buy | Form 4 ↗ |
| Nov 4, 2025 | Thomas J. Hollister Director | BBT Beacon Financial Corporation | Buy | 4,200 | $24.66 | $103.6K Buy | Form 4 ↗ |
| Nov 3, 2025 | William H. Hughes III Director | BBT Beacon Financial Corporation | Buy | 635 | $24.26 | $15.4K Buy | Form 4 ↗ |
| Nov 3, 2025 | Carl M. Carlson CFO & Chief Strategy Officer | BBT Beacon Financial Corporation | Buy | 2,000 | $24.69 | $49.4K Buy | Form 4 ↗ |
| Sep 12, 2025 | Willard I. Hill Jr. Director | BBT Beacon Financial Corporation | Sale | 1,000 | $25.96 | $26.0K Sale | Form 4 ↗ |
| Feb 11, 2025 | Ellen Tulchiner EVP,Head of Cnsmr Lndng&Pymnts | BHLB Beacon Financial Corporation | Sale | 1,052 | $29.97 | $31.5K Sale | Form 4 ↗ |
15 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances